Beyond the bathroom scale
Phase 2 MASH · Published June 7, 2024
Does liver tissue improve, not just body weight?
Subject One arrives carrying a bathroom scale. The next room has microscope slides instead. “Wrong instrument?” he asks. Doctide points to the tissue record. The visitor sets the scale down and starts a new page.
What changes here
Biopsy findings improved in a phase 2 liver study; that is not proof of preventing liver failure or death. [1]
Read the study details & dates
Adults with biopsy-confirmed MASH and F1–F3 fibrosis
293 treated adults received weekly subcutaneous survodutide in three groups or placebo. In the planned-treatment modified intention-to-treat analysis, MASH improvement without worsening fibrosis occurred in 47%, 62% and 43% versus 14%; the dose-response model gave P<0.001. Missing final biopsies counted as nonresponse. These are not the higher percentages from the actual-treatment paired-biopsy analysis. [1] [2] [3]
Why the safety denominators differ
The registry groups serious events by actual maintenance treatment: 93, 69 and 52 survodutide participants and 79 placebo participants. These differ from the randomized planned-treatment groups used above. The reported cancer events occurred in 1/69 and 1/79, respectively; these small counts cannot establish a causal risk comparison. [3]
What this does not establish
MASH is inflammatory fatty-liver disease; fibrosis means scarring. This biopsy endpoint does not establish fewer transplants or deaths. Results should not be generalized to cirrhosis.
Original sources
- Sanyal et al. — phase 2 MASH trial, NEJM, June 7, 2024
- University of Turin repository — full primary MASH manuscript, including Table 2
- ClinicalTrials.gov — NCT04771273
Primary manuscript, methods and safety Table 2 reviewed October 27, 2026; planned-treatment results kept separate from actual-treatment analyses.
Subject One is fictional. Separate studies, species and populations are not a single patient’s experience. How to read the story